DEINOVE creates a subsidiary for its antibiotics program

March 21, 2013

DEINOVE CREATES A SUBSIDIARY FOR ITS ANTIBIOTICS PROGRAM

  • To accelerate research and development of new antibiotics
  • With a dedicated management team led by Alain CHEVALLIER and Dominique LE BELLER
  • DEINOVE owns 49% of new entity, DEINOBIOTICS SAS, and holds the right to buy back the outstanding shares


Paris March 21 2013 - DEINOVE (Alternext Paris: ALDEI), the Deinococcus bacteria company, announced that the Board of Directors has decided to accelerate the development of the company's antibiotics program by establishing a dedicated subsidiary, DEINOBIOTICS, that incorporates the expertise and resources to meet its ambitions in this field.